SOURCE: Paragon Financial Limited

Paragon Financial Limited

February 21, 2012 08:20 ET

Arena Pharmaceuticals and Orexigen Therapeutics Look to Make Headway in Obesity Drug Market

The Paragon Report Provides Equity Research on Arena Pharmaceuticals & Orexigen Therapeutics

NEW YORK, NY--(Marketwire - Feb 21, 2012) - While the North American economy continues to stagnate, the obesity epidemic in the United States and Canada shows no signs of slowing. According to ObesityEpidemic.org, the statistics show that roughly 33% of the US population is obese and 67% of the US population is overweight. According to The Obesity Research Journal, by 2030, 86.3% adults will be overweight or obese and 51.1% will be obese. Looking to combat North America's growing obesity crisis -- and capitalize on a highly lucrative sector -- several biotechnology firms have been working to develop obesity drugs and treatments. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Orexigen Therapeutics Inc. (NASDAQ: OREX). Access to the full company reports can be found at:

www.paragonreport.com/ARNA
www.paragonreport.com/OREX

Orexigen Therapeutics, Inc., a development stage company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Earlier this month the company reached an agreement with U.S. health regulators on the design of a heart-safety trial required for the approval of its experimental obesity drug. Orexigen plans to enroll about 10,000 patients in the placebo-controlled trial for demonstrating that the drug Contrave does not unacceptably increase the risk of major adverse cardiovascular events, Reuters reports.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

In a big month for obesity drug makers, Arena Pharmaceuticals Inc. said an FDA advisory committee will meet in the second quarter to discuss the company's resubmitted application for its weight-loss drug, lorcaserin.

In addition to lorcaserin, Arena Pharmaceuticals is focused on APD811, an internally discovered, orally available agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer